Related Experiment Videos
The effect of hemoglobin concentration on peritoneal mass transfer and drain volumes in continuous ambulatory
A J Hutchison1, N J Ofsthun, D Howarth
1Manchester Royal Infirmary Renal Unit, U.K.
Insights
Hemoglobin levels do not affect peritoneal mass transfer or drain volumes in continuous ambulatory peritoneal dialysis (CAPD) patients. Treatment with recombinant human erythropoietin (rHuEPO) also showed no impact on these parameters.
Area of Science:
- Nephrology
- Dialysis
- Anemia Management
Background:
- Anemia is common in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
- Hemoglobin levels may influence fluid and solute transport across the peritoneum.
- Recombinant human erythropoietin (rHuEPO) is used to treat anemia in CAPD patients.
Purpose of the Study:
- To investigate the relationship between hemoglobin levels and peritoneal mass transfer and drain volumes in CAPD patients.
- To assess the effect of rHuEPO therapy on these parameters.
Main Methods:
- Prospective study comparing CAPD patients with low (Group A, Hb < 8.5 g/dL) vs. high (Group B, Hb > 10.5 g/dL) hemoglobin levels.
- Peritoneal mass transfer and drain volumes were measured.
- A subgroup of anemic patients (Group C) received rHuEPO, with measurements repeated after hemoglobin increase.
Main Results:
- No statistically significant differences in peritoneal mass transfer or drain volumes were observed between the low and high hemoglobin groups.
- rHuEPO therapy did not result in significant changes in these parameters in the treated subgroup.
Conclusions:
- Hemoglobin levels do not appear to influence peritoneal transport of small solutes and water in CAPD patients.
- Effective rHuEPO treatment for anemia does not alter peritoneal fluid or solute dynamics.
Objective:
To determine whether a correlation exists between hemoglobin levels and peritoneal mass transfer or drain volumes in continuous ambulatory peritoneal dialysis (CAPD) patients.
Design:
Prospective study of two groups of CAPD patients, identified on the basis of their stable hemoglobin levels. Group A--hemoglobin less than 8.5 g/dL; Group B--hemoglobin greater than 10.5 g/dL. Peritoneal mass transfer and drain volumes were measured for each patient, after which a subgroup of Group A was treated with rHuEPO (forming Group C) and measurements repeated once hemoglobin had risen by at least 2.0 g/dL.
Setting:
Single renal unit of a university teaching hospital.
Patients:
Twenty-seven patients established on CAPD, selected according to their stable hemoglobin level. Group A--14 patients; Group B--13 patients; Group C (subgroup of A)--8 patients.
Main Outcome Measures:
Difference between peritoneal mass transfer or drain volume in Group A versus Group B, and in Group C before and after rHuEPO therapy. Serum biochemical parameters in Group C before and after rHuEPO therapy.
Results:
No statistically significant differences in any of the parameters measured were found between groups A and B, or before and after rHuEPO therapy in Group C.
Conclusions:
Peritoneal transfer of small solutes and water is not influenced by hemoglobin level, and does not change following otherwise effective treatment with rHuEPO.